to we and year. UC progressing start colitis Amit. II/III status rapidly can indications working additional Crohn's. of on plan that the we are disease. of beyond area our ulcerative Thanks ELEVATE Phase the in medical In get with program patients need to parallel this initiate I'll etrasimod large in etrasimod program particularly to rapidly We're startup benefit Crohn's of unmet toward the who an like executing to
shared. protocols We startup are study in plans, the of additional details and these end will which on regarding overall to trials around timelines the initiate track the designs, the process be for of We finalizing remain program program after year.
diseases body highly and to give severe has of etrasimod's to SXPX that dermatitis. preclinical selective us dermatologic receptors data starting In plan experiential begin experimental with suffering testing benefits inflammatory IIb addition etrasimod at and we in Phase SXPX from evidence and bowel yield a in trial confidence atopic to the unique disease to profile strong A atopic potential an patients to dermatitis. moderate clinical from
efficacy have move field emollients of impact set patients the only dermatologic and atopic simple to safely that a potentially and newer this biologics in from range Current We injectable topical other implications with not oral of as a therapies. once-a-day is may to therapies that well. atopic opportunity significant dermatitis limited manifestations dermatitis forward believe but systemic for there regimen
multi-center patients year. study expectation trial, to inadequate steroids. be which topical The in in as program of to active this the branded etrasimod double-blind will trial atopic doses enrolling have with ADVISE we and patients later mode moderate dermatitis we startup response study of severely testing randomized two a are placebo-controlled the For with the
continue the score of achieving and EASI will The of endpoints observation Approximately an XXX enrolled change the XX-week change will area week from percent XX to in And will a a secondary will include treatment or follow-up proportion baseline be patients and patients pruritus index in be that. for XX. others. endpoint severity score EASI primary among measures eczema period and after four-week period
progress. on We excited you dermatology etrasimod in initiating be to our are to forward look we updating with work and
clinical full believe that the peripherally We receptor. has or gears product significant in associated to the July, treatment or Now, advancement type branded of Phase a bowel be with olorinab, this targeting And to irritable agonist selective a pain two switch trial the potential IIb I'll CAPTIVATE, CBX active cannabinoid initiated pain. highly our abdominal the to treatment IBS. syndrome visceral in of we
and for life. degree majority management most high is of a this as who often abdominal of patients unmet their significantly GI such pain disorders in disease hallmark symptom the IBS. is IBS medical of problematic as there suffer Abdominal describe that impacting frequent need pain quality a We of believe pain
management current cross this predominant because evidence to of Importantly, constipation pain suggests rather olorinab's compound predominant, facets diarrhea mixed. motility, directed mechanism IBS: of potential action to and than is all that has
trial of multi-center Xb olorinab Phase is patients who frequent placebo-controlled The with double-blind CAPTIVATE randomized a XX-week experience in abdominal pain. study IBS
constipation doses three or IBS-C IBS-D. primary in from compared placebo of Average with predominant objective patients administered Pain both include is and The to will weekly efficacy and Abdominal this olorinab the trial of of safety Scale or AAPS or the the predominant diarrhea times assess three improvement is We baseline. and to endpoint daily primary
appropriate. week. on and We trial or availability will program the least data endpoints also a will planning look progress CAPTIVATE on secondary number half as patients of of days of second patients in per be achieve in updating the we looking pain-free improvement of in the We at some XX% who mean of enroll forward change the AAPS The and proportion this approximately you including year. are more XXX key at the to
So the finally, R&D reallocation the front, we like our would on responsibilities discuss management organizational within to of team.
continue portfolio Development to Cabell Dr. prioritization pipeline, overseeing Cabell and as who serve Chris Arena management the and of at month, to will R&D the within chief function As medical has strategy, and and report Dr. Head me shift continue of of external a expansion will as of to officer I President of will this to Research global of functions October Clinical Senior and I XXXX. interactions. since R&D Development, Vice Head served the our
Dr. Cabell Quintiles, and trained management research. XX of at to scientific Arena, is Chris MHS positions focused and cardiologist officer. a a including spent clinical years IQVIA senior joining now medical with chief Prior on degree an Duke variety
As the the and he operations, bioinformatics will clinical clinical oversee CMO safety functions. at Arena, development, the
clinical in Chris almost years be Arena strategic may to patients our responsibility the medical expertise assure and bandwidth Cabell products, partnered populations our flexibility for and across Arena the confident now shifting that our patient serve two I excellence with increases well to oversight culminating large I'm operational efficiency have Dr. our in clinical increases our trials of programs, with and that clinical progression at and the to am the company and group. ultimately will treated As grateful and enrolled, his programs. R&D continue
our of to And for like turn call review now I'd over Kevin to financials. Kevin? the a
